SciClone Pharmaceuticals Inc. strengthened its hand in China with the acquisition of privately held specialty pharmaceutical company NovaMed Pharmaceuticals Inc., of Shanghai, for $61.8 million in up-front cash and stock and a potential $43 million in earn-outs for the 2011 and 2012 fiscal years.